Heart failure & cardiomyopathies
Clinical Profile, Associated Events and Safety of Vericiguat in a Real-World Cohort: The VERITA Study
Authors' conclusion
In clinical practice, treatment with vericiguat is associated with substantial improvements in functional class and quality of life and a reduction in hospitalizations for HF, with a low risk of adverse effects.
Study context
- Population
- Patients with heart failure with reduced ejection fraction (HFrEF) and recent HF worsening episodes requiring intravenous therapy52 with ≥6 months' follow-up
- Participants
- 103 patients
- Outcome
- Change during follow-up (NYHA class, EQ-5D, VAS, HF hospitalizations)
- Follow-up
- Median 303 days
Methodological detailssingle-group, HF outpatient clinic
- Single-group
- HF outpatient clinic
Main finding
As reported in the abstract
- New York Heart Association (NYHA) class III / II from 67.3% / 32.7% to 22.4% / 75.5% at study end
- P < 0.001
- EQ-5D from 0.83 ± 0.13 to 0.87 ± 0.12
- P = 0.032
- Visual analogue scale (VAS) from 60 to 79
- P = 0.005
- HF hospitalizations/decompensations: 2.3 ± 1.4 in previous 12 months, decreased with vericiguat to 0.79 ± 1.14
- P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Target dose of 10 mg achieved | Vericiguat 78.8% |
Safety
| Outcome | Values |
|---|---|
| Symptomatic hypotension; treatment discontinuation; death · study end | Vericiguat Symptomatic hypotension 13.5% · Discontinued treatment 11.5% · Died 7.7% |
- Symptomatic hypotension; treatment discontinuation; death: 50% of deaths for HF
Original publication
Clinical Profile, Associated Events and Safety of Vericiguat in a Real-World Cohort: The VERITA Study. ESC Heart Fail. Published 18 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →